Thursday, November 27, 2014
Galeterone shows activity in a variant form of castration-resistant prostate cancer
… of prostate cancer that is resistant to treatment with hormone therapy (castration-resistant prostate cancer or CRPC).
Associate professor Mary-Ellen Taplin, of the Dana-Farber Cancer Institute … first prostate cancer trial to assess a biomarker, namely AR-V7 in circulating tumour …
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment